We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?
Read MoreHide Full Article
Assertio (ASRT - Free Report) shares ended the last trading session 17% higher at $21.61. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.9% loss over the past four weeks.
Shares of Assertio Holdings, Inc. jumped after Garda Therapeutics raised its buyout offer to $21.80 per share in cash under a revised merger agreement, bringing the total deal value to $153.2 million. The new bid is 21.1% higher than the earlier offer and reflects a significant premium to the stock’s prior trading levels, making the deal more attractive to shareholders. The increase, along with firm financing and a competitive bidding process, boosted confidence that the transaction will go through, pushing the stock price closer to the updated offer level.
This drugmaker is expected to post quarterly loss of $1.91 per share in its upcoming report, which represents a year-over-year change of +9.1%. Revenues are expected to be $10.34 million, down 61% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Assertio, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ASRT going forward to see if this recent jump can turn into more strength down the road.
Assertio is part of the Zacks Medical - Drugs industry. Journey Medical Corporation (DERM - Free Report) , another stock in the same industry, closed the last trading session 1.4% lower at $5.12. DERM has returned 4.9% in the past month.
For Journey Medical, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.07. This represents a change of +61.1% from what the company reported a year ago. Journey Medical currently has a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?
Assertio (ASRT - Free Report) shares ended the last trading session 17% higher at $21.61. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.9% loss over the past four weeks.
Shares of Assertio Holdings, Inc. jumped after Garda Therapeutics raised its buyout offer to $21.80 per share in cash under a revised merger agreement, bringing the total deal value to $153.2 million. The new bid is 21.1% higher than the earlier offer and reflects a significant premium to the stock’s prior trading levels, making the deal more attractive to shareholders. The increase, along with firm financing and a competitive bidding process, boosted confidence that the transaction will go through, pushing the stock price closer to the updated offer level.
This drugmaker is expected to post quarterly loss of $1.91 per share in its upcoming report, which represents a year-over-year change of +9.1%. Revenues are expected to be $10.34 million, down 61% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Assertio, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ASRT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Assertio is part of the Zacks Medical - Drugs industry. Journey Medical Corporation (DERM - Free Report) , another stock in the same industry, closed the last trading session 1.4% lower at $5.12. DERM has returned 4.9% in the past month.
For Journey Medical, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.07. This represents a change of +61.1% from what the company reported a year ago. Journey Medical currently has a Zacks Rank of #3 (Hold).